Physiologically-based pharmacokinetic/pharmacodynamic modeling of meropenem in critically ill patients

Abstract This study aimed to develop a physiologically based pharmacokinetic/pharmacodynamic model (PBPK/PD) of meropenem for critically ill patients. A PBPK model of meropenem in healthy adults was established using PK-Sim software and subsequently extrapolated to critically ill patients based on a...

Full description

Bibliographic Details
Published in:	Scientific Reports
Main Authors:	Yujie Yang, Yirong Wang, Wei Zeng, Jinhua Zhou, Min Xu, Ying Lan, Lvye Liu, Jian Shen, Chuan Zhang, Qin He
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-08-01
Subjects:	Meropenem PBPK/PD Critically ill patients PK-Sim
Online Access:	https://doi.org/10.1038/s41598-024-64223-0

Similar Items

Relationship between Pharmacokinetic/Pharmacodynamic Target Attainment and Microbiological Outcome in Critically Ill COVID-19 Patients with Documented Gram-Negative Superinfections Treated with TDM-Guided Continuous-Infusion Meropenem
by: Maria Sanz Codina, et al.
Published: (2022-07-01)

Physiologically-based pharmacokinetic modeling for single and multiple dosing regimens of ceftriaxone in healthy and chronic kidney disease populations: a tool for model-informed precision dosing
by: Fawaz Alasmari, et al.
Published: (2023-07-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Population pharmacokinetics of meropenem in critically ill patients
by: Rančić Aleksandar, et al.
Published: (2024-07-01)

Pharmacokinetic-pharmacodynamic target attainment analyses as support for meropenem dosing regimens in critically ill adult and elderly patients with Pseudomonas aeruginosa infections
by: Ruyu Tao, et al.
Published: (2025-09-01)

Development and Evaluation of a Physiologically Based Pharmacokinetic Model for Predicting Haloperidol Exposure in Healthy and Disease Populations
by: Mohammed S. Alasmari, et al.
Published: (2022-08-01)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
by: Pasquale Maria Berrino, et al.
Published: (2023-08-01)

Prediction of pharmacokinetic/pharmacodynamic properties of aldosterone synthase inhibitors at drug discovery stage using an artificial intelligence-physiologically based pharmacokinetic model
by: Mengjun Zhang, et al.
Published: (2025-04-01)

Defining Exposure Predictors of Meropenem That Are Associated with Improved Survival for Severe Bacterial Infection: A Preclinical PK/PD Study in Sepsis Rat Model
by: Yan Wang, et al.
Published: (2022-11-01)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
by: Dong-Hwan Lee, et al.
Published: (2021-11-01)

Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling
by: Ruifang Guan, et al.
Published: (2023-11-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

Prediction of the pharmacokinetics, pharmacodynamics and efficacy of a monoclonal antibody, using a physiologically based pharmacokinetic FcRn model.
by: Manoranjenni eChetty, et al.
Published: (2015-01-01)

Real-Time TDM-Based Expert Clinical Pharmacological Advice Program for Attaining Aggressive Pharmacokinetic/Pharmacodynamic Target of Continuous Infusion Meropenem in the Treatment of Critically Ill Patients with Documented Gram-Negative Infections Undergoing Continuous Veno-Venous Hemodiafiltration
by: Milo Gatti, et al.
Published: (2023-10-01)

Torsemide Pharmacometrics in Healthy Adult Populations Including CYP2C9 Genetic Polymorphisms and Various Patient Groups through Physiologically Based Pharmacokinetic-Pharmacodynamic Modeling
by: Seung-Hyun Jeong, et al.
Published: (2022-12-01)

Translational Pharmacokinetic-Pharmacodynamic Modeling of a Novel Oral Dihydroorotate Dehydrogenase (DHODH) Inhibitor, HOSU-53 (JBZ-001)
by: Joo Young Na, et al.
Published: (2025-03-01)

Carbapenem treatment options for metallo-beta-lactamase: drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing Klebsiella pneumoniae
by: Haoyue Che, et al.
Published: (2025-04-01)

Population Pharmacokinetics of Prolonged Infusion for Meropenem: Tailoring Dosing Recommendations for Chinese Critically Ill Patients on Continuous Renal Replacement Therapy with Consideration for Renal Function
by: Peng Y, et al.
Published: (2025-02-01)

In vivo pharmacokinetic and pharmacodynamic study and cutoff of florfenicol against Riemerella anatipestifer in ducks
by: Hui-Lin Zhang, et al.
Published: (2025-01-01)

Continuous vs. intermittent meropenem infusion in critically ill patients with sepsis: a systematic review and meta-analysis of randomized controlled trials with trial sequential analysis
by: Youquan Wang, et al.
Published: (2025-06-01)

In vivo pharmacokinetic and pharmacodynamic profiles of orbifloxacin against Staphylococcus aureus in a neutropenic murine thigh infection model
by: Long-Gen Zhong, et al.
Published: (2025-08-01)

Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Predict the Impact of CYP2C9 Genetic Polymorphisms, Co-Medication and Formulation on the Pharmacokinetics and Pharmacodynamics of Flurbiprofen
by: Ioannis Loisios-Konstantinidis, et al.
Published: (2020-11-01)

Pharmacokinetic/pharmacodynamic evaluation of gamithromycin against rabbit pasteurellosis
by: Xin-Yi Wei, et al.
Published: (2024-04-01)

Measuring Creatinine Clearance Is the Most Accurate Way for Calculating the Proper Continuous Infusion Meropenem Dose for Empirical Treatment of Severe Gram-Negative Infections among Critically Ill Patients
by: Carla Troisi, et al.
Published: (2023-02-01)

A Retrospective Analysis of Intravenous Push versus Extended Infusion Meropenem in Critically Ill Patients
by: Emory G. Johnson, et al.
Published: (2024-09-01)

A methodological review on the pharmacokinetic/pharmacodynamic integration of antibacterial drugs
by: Hongjuan WANG, et al.
Published: (2022-02-01)

Total and Unbound Pharmacokinetics of Cefiderocol in Critically Ill Patients
by: Noël Zahr, et al.
Published: (2022-12-01)

Optimizing Antibiotic Therapy for <i>Stenotrophomonas maltophilia</i> Infections in Critically Ill Patients: A Pharmacokinetic/Pharmacodynamic Approach
by: Helena Barrasa, et al.
Published: (2024-06-01)

Importance of Pharmacokinetic/Pharmacodynamic Concept in Antibiotic Therapy
by: Tuğba Gümüștaș, et al.
Published: (2018-04-01)

Pharmacokinetic and Pharmacodynamic Modeling of Enrofloxacin and Its Metabolite Ciprofloxacin in Pregnant Goats
by: Luis Adrian Ambros, et al.
Published: (2025-06-01)

Pharmacokinetic/pharmacodynamic parameters of vancomycin for predicting clinical outcome of enterococcal bacteremia
by: Eliel Nham, et al.
Published: (2022-08-01)

Suboptimal drug exposure leads to selection of different subpopulations of ceftazidime-avibactam-resistant Klebsiella pneumoniae carbapenemase-producing Klebsiella pneumoniae in a critically ill patient
by: Paolo Gaibani, et al.
Published: (2021-12-01)

Population Pharmacokinetics of Hydroxychloroquine and 3 Metabolites in COVID-19 Patients and Pharmacokinetic/Pharmacodynamic Application
by: Jean Claude Alvarez, et al.
Published: (2022-02-01)

Pharmacokinetics of colistin in patients with multi-drug resistant Gram-negative bacterial infections
by: Harivenkatesh Natarajan, et al.
Published: (2024-12-01)

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
by: Carlijn H. C. Litjens, et al.
Published: (2023-04-01)

Construction of warfarin population pharmacokinetics and pharmacodynamics model in Han population based on Bayesian method
by: Xiaotong Xia, et al.
Published: (2024-06-01)

Pharmacokinetic–Pharmacodynamic Modeling of Midazolam in Pediatric Surgery
by: Carmen Flores-Pérez, et al.
Published: (2023-11-01)

Optimization of Therapy and the Risk of Probiotic Use during Antibiotherapy in Septic Critically Ill Patients: A Narrative Review
by: Maria Ioana Onofrei, et al.
Published: (2023-02-01)

Pharmacokinetic analysis of meropenem therapeutic drug monitoring data (TDM) in critically ill adult patients
by: I. B. Bondareva, et al.
Published: (2022-03-01)

Prevalence of on time administration of carbapenem and its impact on PK/PD target attainment in hospitalized patients: a multicenter retrospective study
by: Jin Song, et al.
Published: (2025-10-01)